Superselective arterial BCNU infusion in the treatment of patients with malignant gliomas.
Retinal and CNS toxicity have been reported with infraophthalmic infusion of BCNU in the treatment of patients with malignant gliomas. It is known, however, that the CNS toxicity can be reduced if the BCNU is dissolved in dextrose in water. This article describes the results from 15 patients who received 42 courses of BCNU administered by supraophthalmic internal carotid, middle cerebral, or posterior cerebral artery infusions. None of the patients developed leukoencephalopathy as demonstrated by CT scanning. The average reduction in tumor volume was 36%, and the median survival time from the date of diagnosis was 73 weeks. These values are comparable to those of a previous group of 20 patients treated with infraophthalmic infusions, with the exception that none of the patients in the present group developed retinal damage.
Clayman
D A
DA
Department of Radiology, New England Medical Center, Boston, MA 02111.
Wolpert
S M
SM
Heros
D O
DO
D000328:Adult; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D002330:Carmustine / Q000008:administration & dosage* / Q000627:therapeutic use; D002343:Carotid Artery, Internal; D002536:Cerebral Arteries; D003131:Combined Modality Therapy; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy* / Q000532:radiotherapy; D006801:Humans; D007261:Infusions, Intra-Arterial; D008297:Male; D008875:Middle Aged
D002330:Carmustine